FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285324269> ?p ?o ?g. }

• W4285324269 endingPage "e35442" @default.
• W4285324269 startingPage "e35442" @default.
• W4285324269 abstract "More sensitive and less burdensome efficacy end points are urgently needed to improve the effectiveness of clinical drug development for Alzheimer disease (AD). Although conventional end points lack sensitivity, digital technologies hold promise for amplifying the detection of treatment signals and capturing cognitive anomalies at earlier disease stages. Using digital technologies and combining several test modalities allow for the collection of richer information about cognitive and functional status, which is not ascertainable via conventional paper-and-pencil tests.This study aimed to assess the psychometric properties, operational feasibility, and patient acceptance of 10 promising technologies that are to be used as efficacy end points to measure cognition in future clinical drug trials.The Method for Evaluating Digital Endpoints in Alzheimer Disease study is an exploratory, cross-sectional, noninterventional study that will evaluate 10 digital technologies' ability to accurately classify participants into 4 cohorts according to the severity of cognitive impairment and dementia. Moreover, this study will assess the psychometric properties of each of the tested digital technologies, including the acceptable range to assess ceiling and floor effects, concurrent validity to correlate digital outcome measures to traditional paper-and-pencil tests in AD, reliability to compare test and retest, and responsiveness to evaluate the sensitivity to change in a mild cognitive challenge model. This study included 50 eligible male and female participants (aged between 60 and 80 years), of whom 13 (26%) were amyloid-negative, cognitively healthy participants (controls); 12 (24%) were amyloid-positive, cognitively healthy participants (presymptomatic); 13 (26%) had mild cognitive impairment (predementia); and 12 (24%) had mild AD (mild dementia). This study involved 4 in-clinic visits. During the initial visit, all participants completed all conventional paper-and-pencil assessments. During the following 3 visits, the participants underwent a series of novel digital assessments.Participant recruitment and data collection began in June 2020 and continued until June 2021. Hence, the data collection occurred during the COVID-19 pandemic (SARS-CoV-2 virus pandemic). Data were successfully collected from all digital technologies to evaluate statistical and operational performance and patient acceptance. This paper reports the baseline demographics and characteristics of the population studied as well as the study's progress during the pandemic.This study was designed to generate feasibility insights and validation data to help advance novel digital technologies in clinical drug development. The learnings from this study will help guide future methods for assessing novel digital technologies and inform clinical drug trials in early AD, aiming to enhance clinical end point strategies with digital technologies.DERR1-10.2196/35442." @default.
• W4285324269 created "2022-07-14" @default.
• W4285324269 creator A5004288211 @default.
• W4285324269 creator A5011973740 @default.
• W4285324269 creator A5013319312 @default.
• W4285324269 creator A5013688813 @default.
• W4285324269 creator A5021526672 @default.
• W4285324269 creator A5024652282 @default.
• W4285324269 creator A5024955315 @default.
• W4285324269 creator A5029281772 @default.
• W4285324269 creator A5029500893 @default.
• W4285324269 creator A5033244241 @default.
• W4285324269 creator A5033525337 @default.
• W4285324269 creator A5034296710 @default.
• W4285324269 creator A5037630087 @default.
• W4285324269 creator A5047845450 @default.
• W4285324269 creator A5048308040 @default.
• W4285324269 creator A5057050843 @default.
• W4285324269 creator A5057483408 @default.
• W4285324269 creator A5060018704 @default.
• W4285324269 creator A5068784389 @default.
• W4285324269 creator A5071991310 @default.
• W4285324269 creator A5072359600 @default.
• W4285324269 creator A5074046220 @default.
• W4285324269 creator A5074363867 @default.
• W4285324269 creator A5079735833 @default.
• W4285324269 creator A5083708554 @default.
• W4285324269 creator A5084337429 @default.
• W4285324269 creator A5086714957 @default.
• W4285324269 creator A5087787915 @default.
• W4285324269 date "2022-08-10" @default.
• W4285324269 modified "2023-09-26" @default.
• W4285324269 title "Description of the Method for Evaluating Digital Endpoints in Alzheimer Disease Study: Protocol for an Exploratory, Cross-sectional Study" @default.
• W4285324269 cites W1747703209 @default.
• W4285324269 cites W1847168837 @default.
• W4285324269 cites W1853705225 @default.
• W4285324269 cites W1973109217 @default.
• W4285324269 cites W1973798645 @default.
• W4285324269 cites W1974288165 @default.
• W4285324269 cites W1976074727 @default.
• W4285324269 cites W1979899459 @default.
• W4285324269 cites W1991952617 @default.
• W4285324269 cites W1999428333 @default.
• W4285324269 cites W2002353920 @default.
• W4285324269 cites W2002481697 @default.
• W4285324269 cites W2008854521 @default.
• W4285324269 cites W2014886338 @default.
• W4285324269 cites W2047202120 @default.
• W4285324269 cites W2056151297 @default.
• W4285324269 cites W2058161128 @default.
• W4285324269 cites W2058190976 @default.
• W4285324269 cites W2060863737 @default.
• W4285324269 cites W2064691186 @default.
• W4285324269 cites W2082494913 @default.
• W4285324269 cites W2083762755 @default.
• W4285324269 cites W2087314153 @default.
• W4285324269 cites W2091122245 @default.
• W4285324269 cites W2105121811 @default.
• W4285324269 cites W2105382574 @default.
• W4285324269 cites W2115300091 @default.
• W4285324269 cites W2138883123 @default.
• W4285324269 cites W2146249493 @default.
• W4285324269 cites W2148080316 @default.
• W4285324269 cites W2149564130 @default.
• W4285324269 cites W2152541739 @default.
• W4285324269 cites W2157289187 @default.
• W4285324269 cites W2158869838 @default.
• W4285324269 cites W2159929658 @default.
• W4285324269 cites W2167311298 @default.
• W4285324269 cites W2170847899 @default.
• W4285324269 cites W2177693422 @default.
• W4285324269 cites W2205216748 @default.
• W4285324269 cites W2342143408 @default.
• W4285324269 cites W2619097621 @default.
• W4285324269 cites W2750510345 @default.
• W4285324269 cites W2798054687 @default.
• W4285324269 cites W2801987007 @default.
• W4285324269 cites W2803176146 @default.
• W4285324269 cites W2897050989 @default.
• W4285324269 cites W2934663403 @default.
• W4285324269 cites W2950283932 @default.
• W4285324269 cites W2952778987 @default.
• W4285324269 cites W2965472879 @default.
• W4285324269 cites W3091584968 @default.
• W4285324269 cites W3156753933 @default.
• W4285324269 cites W3158697864 @default.
• W4285324269 cites W3184203554 @default.
• W4285324269 cites W3207475493 @default.
• W4285324269 cites W971247292 @default.
• W4285324269 doi "https://doi.org/10.2196/35442" @default.
• W4285324269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35947423" @default.
• W4285324269 hasPublicationYear "2022" @default.
• W4285324269 type Work @default.
• W4285324269 citedByCount "0" @default.
• W4285324269 crossrefType "journal-article" @default.
• W4285324269 hasAuthorship W4285324269A5004288211 @default.
• W4285324269 hasAuthorship W4285324269A5011973740 @default.
• W4285324269 hasAuthorship W4285324269A5013319312 @default.

• next